Revelation Biosciences
REVB
2 hedge funds and large institutions have $589K invested in Revelation Biosciences in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
50% less funds holding
Funds holding: 4 → 2 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
84% less capital invested
Capital invested by funds: $3.57M → $589K (-$2.98M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$120K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$907K |
| 2 |
Citigroup
New York
|
-$287K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$135K |
| 4 |
HF
HRT Financial
New York
|
-$12K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$6K |
REVB Hedge Fund Activity: Q3 2022 in Review
2 institutional investors reported a position in Revelation Biosciences (REVB) for Q3 2022, worth a combined $589K — down 84% from $3.57M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of REVB and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was State Street, opening a new position worth an estimated $120K. The largest seller was Monashee Investment Management, exiting entirely with an estimated $907K sold.
- 2 institutional investors held Revelation Biosciences (REVB) as of Q3 2022, down from 4 in Q2 2022.
- Funds reported $589K of Revelation Biosciences stock for Q3 2022, down 84% quarter-over-quarter.
- 1 fund opened new Revelation Biosciences positions in Q3 2022 and 3 closed out, a net change of -2 holders.
- The largest Revelation Biosciences buyer in Q3 2022 was State Street, an estimated $120K added.
- The largest Revelation Biosciences seller in Q3 2022 was Monashee Investment Management, an estimated $907K sold.
Based on aggregated 13F filings for Q3 2022.